AU2018313028B2 - Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain - Google Patents

Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain Download PDF

Info

Publication number
AU2018313028B2
AU2018313028B2 AU2018313028A AU2018313028A AU2018313028B2 AU 2018313028 B2 AU2018313028 B2 AU 2018313028B2 AU 2018313028 A AU2018313028 A AU 2018313028A AU 2018313028 A AU2018313028 A AU 2018313028A AU 2018313028 B2 AU2018313028 B2 AU 2018313028B2
Authority
AU
Australia
Prior art keywords
leu
thr
lys
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018313028A
Other languages
English (en)
Other versions
AU2018313028A1 (en
Inventor
Jody Berry
Matteo Binda
Elizabeth Booth
Vincenzo Favaloro
John A. Hall
Peter Schwind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Diagnostic Solutions Inc
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of AU2018313028A1 publication Critical patent/AU2018313028A1/en
Application granted granted Critical
Publication of AU2018313028B2 publication Critical patent/AU2018313028B2/en
Priority to AU2023204121A priority Critical patent/AU2023204121A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018313028A 2017-08-10 2018-06-01 Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain Active AU2018313028B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023204121A AU2023204121A1 (en) 2017-08-10 2023-06-28 Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10
US62/543,788 2017-08-10
PCT/IB2018/053939 WO2019030581A1 (en) 2017-08-10 2018-06-01 COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204121A Division AU2023204121A1 (en) 2017-08-10 2023-06-28 Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

Publications (2)

Publication Number Publication Date
AU2018313028A1 AU2018313028A1 (en) 2020-02-20
AU2018313028B2 true AU2018313028B2 (en) 2023-05-25

Family

ID=62846219

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018313028A Active AU2018313028B2 (en) 2017-08-10 2018-06-01 Compositions, methods and/or kits comprising a recombinant human CD38-extracellular domain
AU2023204121A Pending AU2023204121A1 (en) 2017-08-10 2023-06-28 Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023204121A Pending AU2023204121A1 (en) 2017-08-10 2023-06-28 Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

Country Status (18)

Country Link
US (3) US11708418B2 (enExample)
EP (3) EP3587445B1 (enExample)
JP (3) JP6833851B2 (enExample)
KR (2) KR20240015159A (enExample)
CN (2) CN117820498A (enExample)
AR (1) AR112357A1 (enExample)
AU (2) AU2018313028B2 (enExample)
BR (1) BR112020002636A2 (enExample)
CA (1) CA3070789A1 (enExample)
EA (1) EA202090265A1 (enExample)
ES (2) ES2973864T3 (enExample)
HU (1) HUE065510T2 (enExample)
MX (3) MX2020001489A (enExample)
PL (1) PL3587445T3 (enExample)
PT (1) PT3587445T (enExample)
TW (1) TW201910349A (enExample)
UY (1) UY37757A (enExample)
WO (1) WO2019030581A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973864T3 (es) * 2017-08-10 2024-06-24 Grifols Diagnostic Solutions Inc Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano
KR102391992B1 (ko) 2018-02-20 2022-04-29 에프. 호프만-라 로슈 아게 재조합 ＧｐＩｂα 수용체 단백질을 포함하는 조성물
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
JP2023541254A (ja) * 2020-09-10 2023-09-29 キャシ ファーマシューティカルズ インコーポレイテッド 血液スクリーニング方法
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
CN120712276A (zh) * 2023-02-16 2025-09-26 株式会社Dnt 用于治疗自身免疫性疾病的包含cd38或其片段的组合物
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071355A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
TR201910145T4 (tr) * 2006-09-26 2019-08-21 Genmab As Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik.
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR101580937B1 (ko) * 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
US20100239578A1 (en) * 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
ES2604309T3 (es) 2008-10-01 2017-03-06 Amgen Research (Munich) Gmbh Anticuerpo biespecífico de cadena sencilla PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinaxCD3, EpCAMxCD3, IGF-1RxCD3 o FAPALPHA xCD3 específico entre especies
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
KR101926663B1 (ko) * 2010-02-19 2018-12-07 젠코어 인코포레이티드 신규의 ＣＴＬＡ４-Ｉｇ 이뮤노어드헤신
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
CN104271757B (zh) * 2012-02-06 2020-06-09 印希彼有限公司 Cd47抗体及其使用方法
HUE053362T2 (hu) * 2012-04-27 2021-06-28 Novo Nordisk As Emberi CD30-ligand antigént kötõ fehérjék
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
US9599606B2 (en) * 2014-06-10 2017-03-21 The Board Of Regents Of The University Of Texas System ADP-ribose detection reagents
SG11201609876TA (en) * 2014-06-18 2017-01-27 Einstein Coll Med Syntac polypeptides and uses thereof
JP6857603B2 (ja) * 2014-11-18 2021-04-14 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｃｄ１４７抗体、方法及び使用
US10806787B2 (en) * 2015-02-16 2020-10-20 Pharma Foods International Co., Ltd. Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
US9834583B2 (en) * 2015-03-16 2017-12-05 The Catholic University Of America Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
RU2739163C2 (ru) * 2015-03-23 2020-12-21 Байер Фарма Акциенгезельшафт Анти-сеасам6 антитела и их применения
CN111320693B (zh) * 2015-09-08 2023-04-07 卫材R&D管理有限公司 抗EphA4抗体
US10865249B2 (en) * 2015-11-10 2020-12-15 University Medical Center Hamburg-Eppendorf Antigen-binding polypeptides directed against CD38
ES2973864T3 (es) * 2017-08-10 2024-06-24 Grifols Diagnostic Solutions Inc Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071355A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIRA TOHGO ET AL, JOURNAL OF BIOLOGICAL CHEMISTRY, US, (1997-02-14), vol. 272, no. 7, doi:10.1074/jbc.272.7.3879, ISSN 0021-9258, pages 3879 - 3882 *
J. DECKERT ET AL, CLINICAL CANCER RESEARCH, US, (2014-09-01), vol. 20, no. 17, doi:10.1158/1078-0432.CCR-14-0695, ISSN 1078-0432, pages 4574 - 4583 *
KHOO K M ET AL, PROTEIN EXPRESSION AND PURIFICAT, ACADEMIC PRESS, SAN DIEGO, CA, (2005-04-01), vol. 40, no. 2, doi:10.1016/J.PEP.2004.11.010, ISSN 1046-5928, pages 396 - 403 *

Also Published As

Publication number Publication date
WO2019030581A1 (en) 2019-02-14
CN109790210A (zh) 2019-05-21
PT3587445T (pt) 2024-03-14
KR102631281B1 (ko) 2024-01-30
JP2023041802A (ja) 2023-03-24
JP2019527533A (ja) 2019-10-03
EP3587445B1 (en) 2023-12-13
CN117820498A (zh) 2024-04-05
PL3587445T3 (pl) 2024-04-29
CN109790210B (zh) 2024-03-26
HUE065510T2 (hu) 2024-05-28
US11708418B2 (en) 2023-07-25
AR112357A1 (es) 2019-10-23
TW201910349A (zh) 2019-03-16
MX2024008109A (es) 2024-07-19
AU2023204121A1 (en) 2023-07-20
KR20200035194A (ko) 2020-04-02
ES2973864T3 (es) 2024-06-24
EP4296680A2 (en) 2023-12-27
KR20240015159A (ko) 2024-02-02
EP4296680A3 (en) 2024-03-20
MX2020001489A (es) 2020-03-20
US20240092929A1 (en) 2024-03-21
MX2024005669A (es) 2024-05-30
JP7289328B2 (ja) 2023-06-09
ES2911243T3 (es) 2022-05-18
EP3587445A1 (en) 2020-01-01
CA3070789A1 (en) 2019-02-14
AU2018313028A1 (en) 2020-02-20
EA202090265A1 (ru) 2020-06-05
JP6833851B2 (ja) 2021-02-24
US20240228651A9 (en) 2024-07-11
EP3464343B1 (en) 2022-03-23
UY37757A (es) 2018-11-30
US20240132616A1 (en) 2024-04-25
BR112020002636A2 (pt) 2020-07-28
US20210198376A1 (en) 2021-07-01
JP2021088567A (ja) 2021-06-10
EP3464343A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
US20240092929A1 (en) Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
Ko et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
US10323069B2 (en) Senecavirus A antigens and methods of use
Greidinger et al. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen
US20140161796A1 (en) Single chain proteins with c-terminal modifications
US6846637B1 (en) Fas peptides and antibodies for modulating apoptosis
JP2023057154A (ja) 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原
JP2023514270A (ja) 免疫グロブリン検出と関連する療法
US8183055B2 (en) Peptide aptamer for neutralizing the binding of platelet antigen specific antibodies and diagnostic and therapeutic applications containing the same
BR122024021835A2 (pt) Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão.
BR122024021803A2 (pt) Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão
Ramezani et al. Efficient detection of eukaryotic calcium-sensing receptor (CaSR) by polyclonal antibody against prokaryotic expressed truncated CaSR
Terasawa et al. Preferential recognition of isocitrate dehydrogenase by a rabbit monoclonal antibody (ab124797) against the C-terminal peptide of RANKL

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)